Valuation : GI Dynamics, Inc.

Market Cap 4L 4L 4L 3L 6L 4.21Cr 6L 42.68L 16.41L 2.14Cr 16.54L 16.18L 6.77Cr P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 32.79L 28.26L 26.75L 24.25L 45.5L 31Cr 45.73L 3.18Cr 1.22Cr 16Cr 1.23Cr 1.2Cr 50Cr EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member - 20/10/2020
Director/Board Member - -
Director/Board Member 69 01/10/2023

Financials

2019 2020
Net sales - -
Net income -1.73Cr -1.49Cr -1.41Cr -1.28Cr -2.4Cr -165.59Cr -2.42Cr -17Cr -6.46Cr -84Cr -6.51Cr -6.37Cr -266.21Cr -1.11Cr -95.95L -90.85L -82.35L -1.54Cr -106.39Cr -1.55Cr -11Cr -4.15Cr -54Cr -4.18Cr -4.09Cr -171.03Cr
Net Debt 28.87L 24.87L 23.55L 21.35L 40.05L 28Cr 40.25L 2.8Cr 1.08Cr 14Cr 1.08Cr 1.06Cr 44Cr 28.39L 24.46L 23.16L 20.99L 39.38L 27Cr 39.58L 2.75Cr 1.06Cr 14Cr 1.07Cr 1.04Cr 44Cr
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!